Conventional and unconventional treatments for migraine
DOI:
https://doi.org/10.12775/JEHS.2023.19.01.020Keywords
acute migraine attack, migraine treatment, migraine headache, headacheAbstract
Migraine is one of the leading causes of disability in humans. It causes significant deterioration in patients' lives and prevents daily functioning. Its main symptoms include photophobia, an enormous stabbing headache, nausea and vomiting. In addition, it can be accompanied by tinnitus, visual disturbances or dizziness. Before diagnosing migraine, serious intracranial pathology or other neurological conditions should be ruled out. Treatment of acute migraine is difficult due to significant rates of nonresponse to medications and the difficulty in predicting individual response to a particular agent or dose. A new class of drugs, calcitonin gene-related peptide (CGRP) antagonists, has been approved for the prevention of migraine in adults. In contrast, effective first-line therapies for mild to moderate migraine are over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and combination analgesics containing paracetamol, aspirin and caffeine.
References
Peters GL. Migraine overview and summary of current and emerging treatment options. Am J Manag Care. 2019 Jan;25(2 Suppl):S23-S34. PMID: 30681821.
Digre KB. What's New in the Treatment of Migraine? J Neuroophthalmol. 2019 Sep;39(3):352-359. doi: 10.1097/WNO.0000000000000837. PMID: 31393282.
Holland PR, Goadsby PJ. Targeted CGRP small molecule antagonists for acute migraine therapy. Neurotherapeutics. 2018;15:304-312.
The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930-945.
Do TP, Hvedstrup J, Schytz HW. Botulinum toxin: a review of the mode of action in migraine. Acta Neurol Scand. 2018;137:442-451.
Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49(suppl 1):S21-S33. doi: 10.111/j.1526-4610.2008.01336.x.
Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache. 2016;56(7):1194-1200. doi: 10.1111/head.12870.
MacGregor EA. Migraine. Ann Intern Med. 2017;166(7):ITC49-ITC64. doi: 10.7326/AITC201704040.
Rizzoli P. Preventive pharmacotherapy in migraine. Headache. 2014;54(2):364-369. doi: 10.1111/head.12273.
Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157-1168. doi: 10.1111/j.1526-4610.2008.0121x.
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930-945. doi: 10.1111/j.1526-4610.2012.02185.x.
Gilmore B, Michael M. Treatment of acute migraine headache. Am Fam Physician. 2011 Feb 1;83(3):271-80.Erratum in: Am Fam Physician. 2011 Oct 1;84(7):738. PMID: 21302868.
Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369-1373.
Goadsby PJ, Zanchin G, Geraud G, et al. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan [published correction appears in Cephalalgia. 2008;28(6):679]. Cephalalgia. 2008;28(4):383-391.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Katarzyna Mielniczek, Diana Dołomisiewicz, Weronika Dalmata, Ilona Gąbka, Jan Dąbrowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 238
Number of citations: 0